LAUSR

BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL

Sign Up to like & get
recommendations!
1 Published in 2022 at "Cancer Discovery"

DOI: 10.1158/2159-8290.cd-21-1566

Abstract: BCL10 mutations in diffuse large B-cell lymphoma (DLBCL) fall into two classes, with both conferring BTK inhibitor resistance but only truncation mutations conferring MALT1 dependency, suggesting use of these mutation classes as precision therapy biomarkers. read more here.

Keywords: precision therapy; mutations define; bcl10 mutations;